San Antonio and Boston based Intrinsic Imaging, an FDA audited, ISO 9001 and ISO 13485 certified imaging core lab specializing in providing imaging core lab services for clinical trials, has announced that it’s been awarded a multicenter Phase I/II clinical trial designed to evaluate a new therapy to treat patients with metastatic colorectal cancer (mCRC). This study will utilize a novel investigational biologic treatment for patients with unresectable liver metastases in patients with colorectal cancer. During the trial, Intrinsic Imaging will process all images and evaluate treatment response of the patient’s metastatic cancer.
“Advances in medical research have created several new options focused on the treatment of metastatic colorectal cancer,” says Dr. Amit Mehta, Intrinsic Imaging’s Chief Medical Officer and Vice-President, Radiology. “There remain, however, significant challenges in achieving long-term survival in those patients with metastatic disease. The continued development and evaluation of novel therapies is necessary to benefit patients suffering from this disease.“
Intrinsic Imaging’s a team of more than sixty board-certified diagnostic radiologists sub-specialize in imaging all therapeutic areas, including, Oncology, Cardiovascular and Thoracic, Central Nervous System, Gastrointestinal & Genitourinary, Musculoskeletal, Medical Devices, and others, The Intrinsic Oncology team consists of 12 fellowship-trained board-certified radiologists, and eight board-certified interventional radiologists who have in-depth experience in colorectal, pancreatic, breast, lung, ovarian and prostate cancer, among others.
“Colorectal cancer (CRC) continues to be a global public health problem with over 1 million new cases diagnosed each year,” says Intrinsic Imaging President and Chief Operating Officer Todd A. Joron, BSc. MBA. “Intrinsic Imaging is dedicated to applying our therapeutic and regulatory expertise throughout this clinical trial towards assisting in the development of a new effective therapy to treat patients with metastatic colorectal cancer.”
Intrinsic Imaging’s etrials CIMS imaging solution by Merge HealthCare is a comprehensive platform to manage all imaging aspects of a clinical trial. Merge Healthcare develops and integrates information technology to create a better electronic healthcare experience. Merge products, ranging from standards-based development toolkits to sophisticated clinical applications, have been used by healthcare providers, vendors and researchers worldwide for over 20 years.
The CIMS functionality combines image submission, image storage in a vendor-neutral DICOM archive, and image analysis and viewers along with a robust data management/EDC tool-set, and enables Intrinsic Imaging’s radiology experts to more efficiently and economically execute the imaging portion of a clinical trial. Intrinsic Imaging CIMS is integrated with etrials EDC and provides end-to-end visibility to all data in a clinical trial.
Intrinsic Imaging’s team of more than sixty board-certified diagnostic radiologists are proficient in robust and scalable clinical imaging technologies; with sub-specializations in breast, cardiovascular, chest, gastrointestinal, genitourinary, head and neck, musculoskeletal, neuroradiology, pediatric, and interventional radiology; and are experts in all therapeutic areas, with FDA audited, ISO 9001:2008 and ISO 13485:2003 certified, GAMP 5 medical imaging laboratories in San Antonio and Boston. Together with the company’s ISO certified and registered quality management systems, Intrinsic Imaging is positioned to provide pharmaceutical and biotech sponsors with comprehensive first-tier imaging core lab services around the world across all therapeutic areas.
About Intrinsic Imaging’s Executive Team
Dr. Amit Mehta completed his residency in Diagnostic Radiology at Harvard Medical School’s Massachusetts General Hospital, where he also completed a fellowship in Vascular and Interventional Radiology, for which he possesses a Certificate of Additional Qualification by the American Board of Radiology. Dr. Mehta has co-authored three textbooks in Radiology, is widely published in peer-reviewed journals for which he now serves as a reviewer, and currently is appointed as a SBIR/STTR reviewer for the National Institutes of Health. Dr. Mehta was selected in 2010 as one of the “Top 40 under 40” by the San Antonio Business Journal.
Todd A. Joron has 28 years of experience within international Contract Research Organizations (CROs) specializing in the design, development, and delivery of effective industry-changing technology solutions for the pharmaceutical industry. Mr. Joron was most recently Corporate Vice President within PAREXEL — one of the world’s largest public CROs. At PAREXEL, Mr. Joron was General Manager of their Perceptive eClinical technology division, driving significant growth of their global offerings that included Medical Imaging, Clinical Trial Management Systems, Interactive Voice Response Systems and Integration Services. Mr. Joron was previously Vice President and Scientific Director of the Life Sciences Division at Management Science Associates, Inc., Senior Vice President of Sales and Marketing at TissueInformatics Inc., and President and CEO of BiblioMondo. Also previously, Mr. Joron was General Manager of the Scientific Software Division within Phoenix International Life Sciences (now MDS Pharma), a large multi-national CRO. He holds Bachelor of Science degrees in Chemistry and in Biology and a Master’s degree in Business Administration.
The video below provides an overview of colon cancer with Dr. Howard Schecter: